Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Drugmaker Endo International plc said on Tuesday it had agreed to pay up to $65 million to resolve claims by the state of Florida and local governments that the drugmaker helped fuel the U.S. opioid epidemic.

Drugmaker Endo signs $65 million opioid settlement with Florida

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Florida. The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Florida and its subdivisions in exchange for a total payment of up to $65 million.

Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims

Endo International (ENDP) closed at $3.27 in the latest trading session, marking a -1.8% move from the prior day.

Endo International (ENDP) Stock Sinks As Market Gains: What You Should Know

DUBLIN, Jan. 13, 2022 /PRNewswire/ -- Pharmacokinetic simulation modeling study predicted more frequent administration with shorter dosing intervals (8 weeks vs. 10 weeks) would reduce serum testosterone fluctuations and elevate testosterone concentrations at the end of each maintenance dosing interval while maintaining acceptable levels of overall testosterone exposure Endo International plc (NASDAQ:ENDP) announced today the publication of data from a population pharmacokinetic (PK) modeling and simulation study, evaluating potential dosing flexibility of AVEED® (testosterone undecanoate) in hypogonadal males.

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022.

Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- The campaign features real Dupuytren's contracture (DC) patients and aims to address patient complacency, correct myths and misinformation and highlight the Tabletop Test Dupuytren's contracture is a progressive hand condition that affects an estimated 14 million Americans Endo International plc (NASDAQ: ENDP) announced today the launch of its newest television commercial and disease awareness campaign, Watching Education Unfold. The campaign educates people about Dupuytren's contracture (DC), a progressive hand condition that affects an estimated 14 million Americans.

Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold

DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. "We're proud to provide families with a generic option of this important medication," said Jon Holden, Senior Vice President and General Manager, Generics at Endo.

Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m.

Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference

Endo is to pay $63 million to Texas to settle claims made by the state and counties that the company was implicit in fueling the opioid crisis in the state.

Endo will pay $63M to Texas as part of a settlement

(Reuters) -Endo International Plc has agreed to pay $63 million to resolve claims by the state of Texas and local governments that the drugmaker helped fuel the U.S. opioid epidemic, the state's attorney general said on Thursday.

Drugmaker Endo strikes $63 million opioid settlement with Texas

DUBLIN, Dec. 23, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas. The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Texas and its subdivisions in exchange for a total payment of $63 million.

Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims

DUBLIN, Dec. 23, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of cenobamate on an exclusive basis in Canada.  Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada related to cenobamate.

Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago.

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

ANI Pharma

Arlo Technologies Inc

Customers Bancorp

CommVault Systems

KAR Auction Services

Ranger Oil Corp

With 2021 coming to a close and a new year upon us, it's time to get a head start on some of the best small-cap stocks to buy. The post 7 of the Best Small-Cap Stocks to Buy Before 2022 appeared first on InvestorPlace.

7 of the Best Small-Cap Stocks to Buy Before 2022

DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California trial court issuing a final ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI), are not liable. "We are very pleased with the trial court's final ruling and agree with its conclusion that the plaintiffs failed to present evidence demonstrating false or misleading marketing by Endo or a plausible causal link between Endo's marketing and opioid abuse and misuse," said Matthew J.

Endo Announces Favorable Final Ruling in California State Court Opioid Trial

Investors need to pay close attention to for Endo International (ENDP) stock based on the movements in the options market lately.

Do Options Traders Know Something About Endo International (ENDP) Stock We Don't?

Endo (ENDP) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Endo (ENDP)

DUBLIN, Nov. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS). The data were highlighted in five oral presentations during the meeting, which took place virtually November 19-21, 2021.

Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par's calcitonin salmon injection is AP-rated to Viatris' MIACALCIN® and is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required.

Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection

Liquidia Technologies Inc

New Gold

The Real Brokerage Inc.

ReTo Eco-Solutions

Can you make money in the stock market with a full time job? The post Best Penny Stocks To Buy With A Full-Time Job?

Best Penny Stocks To Buy With A Full-Time Job? 5 Hit It Big In Q4 2021

Agreement to fund expansion of Rochester, MI facility to support fill-finish manufacturing of both mRNA and adenovirus vaccines DUBLIN, Nov. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (Endo) today announced that its subsidiary, Par Sterile Products, LLC (Par Sterile), has entered into a cooperative agreement to expand its sterile fill-finish manufacturing production capacity and capabilities at its Rochester, Michigan plant to support the U.S. government's national defense efforts regarding production of critical medicines advancing pandemic preparation. Under the terms of the agreement, Par Sterile's Rochester facility will establish a new sterile fill-finish manufacturing asset capable of processing liquid or lyophilized products requiring Biosafety Level (BSL) 2 containment.

Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines

CBRE Group

ON Semiconductor

Penske Automotive Group

SM Energy

Endo International (ENDP), SM Energy (SM), CBRE Group (CBRE), ON Semiconductor (ON) and Penske Automotive Group (PAG) are five stocks with explosive relative price strength.

5 Stocks Investors Must Buy for Relative Price Strength

Does Endo International (ENDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Endo International (ENDP) is a Great Choice

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Endo International (ENDP) Crossed Above the 200-Day Moving Average: What That Means for Investors

DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT®, vasopressin injection, USP, vial presentations to healthcare providers through Premier's Premier ProRx® program, helping to maintain supply continuity for a medication needed in critical care, including some of the most acute cases of COVID-19. "We're pleased to join Premier in addressing industry drug shortages and serving as a guaranteed supplier of VASOSTRICT ® —proudly produced in our Rochester, MI facility," said Scott Sims, Senior Vice President and General Manager, Sterile Injectables at Endo.

News for Endo International Stock (ENDP)